深度学习量化转移性结直肠癌肿瘤负荷:CAIRO3试验中的预后价值与维持治疗获益
该探索性分析纳入CAIRO3试验中具有肝和/或肺转移的104例mCRC患者,利用深度学习分割模型量化总肿瘤数目(TTN)和总体积(TTV),评估其预后及预测价值。结果显示较高的TTN和TTV与较短的PFS和OS独立相关,且低TTV患者从维持治疗中获得的1年PFS获益更显著(交互作用P=0.0002)。
要点
- TTN和TTV是mCRC独立的预后因素,数值越高预后越差。
- 低TTV患者从维持治疗中获得的1年PFS获益更明显。
- TTV可能作为预测维持治疗获益的生物标志物。
核心结论
- 较高的肿瘤负荷(以数目或体积量化)与mCRC患者较差的PFS和OS独立相关。
- 低肿瘤负荷(尤其是低TTV)患者从维持治疗中获益最大,支持TTV作为预测性生物标志物的潜力。
研究设计与样本
- CAIRO3试验的探索性分析,纳入具有肝和/或肺转移的mCRC患者104例(中位年龄64岁,65%男性)。
- 所有病灶经自动深度学习分割模型计数并量化体积,采用Cox回归评估TTN和TTV的预后价值及与治疗臂的交互作用。
主要发现
- 共分割3989个转移病灶,随机化时中位TTN为10,中位TTV为37 mL。
- 较高的TTN和TTV与较短的PFS相关(TTN p=0.006;TTV p=0.2)和OS相关(TTN p=0.005;TTV p=0.001)。
- 多变量分析中,TTN和TTV均为PFS/OS的独立预后因素。
- 低TTV患者维持治疗的1年PFS获益更显著(交互作用P=0.0002)。
临床怎么用
- 可考虑使用深度学习分割模型量化TTN和TTV以评估mCRC患者预后。
- 低TTV患者可能更适合接受维持治疗,但需进一步验证。
局限性
- 探索性分析,样本量有限(104例),需更大规模研究验证。
- TTV对PFS的预后价值在单变量分析中未达统计学显著性(p=0.2)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Total tumor number (TTN) and total tumor volume (TTV) reflect tumor burden and have been linked to outcomes in metastatic colorectal cancer (mCRC). We hypothesize that these measures can identify patients who benefit most from maintenance therapy. This exploratory analysis assessed the prognostic and predictive value of TTN and TTV in mCRC. METHODS: Patients with liver and/or lung metastases from the CAIRO3 trial, which randomized between maintenance therapy and observation, were included. All lesions were counted, and their volumes were quantified using automated deep-learning segmentation models. Cox regression models were used to assess the prognostic value of TTN and TTV for progression-free (PFS) and overall survival (OS), as well as potential interactions with treatment arm (maintenance vs observation). RESULTS: A total of 3989 metastatic lesions were segmented in 104 patients (median age, 64 years; 65% male). At randomization, median TTN was 10 and median TTV was 37 mL. Higher TTN and TTV were associated with shorter PFS (TTN p = 0.006; TTV p = 0.2) and OS (TTN p = 0.005; TTV p = 0.001). In multivariable analyses, both TTN and TTV were independently prognostic for PFS/OS. The 1-year PFS benefit of maintenance therapy was more pronounced in patients with lower TTV (Pinteraction=0.0002). DISCUSSION: This exploratory analysis showed that a higher tumor burden, quantified by number or volume, was independently associated with poor outcomes. Patients with lower tumor burden, especially lower TTV, appeared to derive the greatest benefit from maintenance therapy, supporting their potential as predictive biomarkers.
引用
- Al-Toma D, Kemna R, Ali M, et al. Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial. Eur J Cancer. 2026. PMID: 41819026. doi:10.1016/j.ejca.2026.116668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。